TransMedics Group (NASDAQ:TMDX) Downgraded to "Market Perform" Rating by Oppenheimer

Key Points

• Oppenheimer downgraded TransMedics Group from "outperform" to "market perform"; analysts are split (six Buy, six Hold) leaving a consensus rating of Moderate Buy and a consensus price target of $148.78.
• Q1 results missed expectations—EPS $0.30 vs. $0.62 expected and revenue $173.93M (vs. $174.48M)—though revenue was up 21.2% year‑over‑year; the stock opened at $94.93 with a 1‑year range of $91.01–$156.00.
• Insiders have been net sellers (16,205 shares, ~$2.35M, in the last 90 days) while institutional ownership is very high (reported at 99.67%), with large funds such as Goldman Sachs increasing their stakes.

TransMedics Group (NASDAQ:TMDX - Get Free Report) was downgraded by analysts at Oppenheimer from an "outperform" rating to a "market perform" rating in a report released on Wednesday, Marketbeat.com reports.

A number of other research firms also recently issued reports on TMDX. Stifel Nicolaus raised their price target on TransMedics Group from $115.00 to $130.00 and gave the stock a "hold" rating in a research note on Monday, March 9th. Piper Sandler raised their price target on TransMedics Group from $140.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. Needham & Company LLC raised their price target on TransMedics Group from $166.00 to $174.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Wall Street Zen downgraded TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday, February 28th. Finally, TD Cowen reiterated a "buy" rating on shares of TransMedics Group in a research report on Monday, March 16th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $148.78.

TransMedics Group Stock Performance

TMDX stock opened at $94.93 on Wednesday. The company has a market cap of $3.28 billion, a P/E ratio of 19.37 and a beta of 2.07. TransMedics Group has a 1 year low of $91.01 and a 1 year high of $156.00. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59. The stock's fifty day moving average price is $116.57 and its 200-day moving average price is $125.96.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.62 by ($0.32). The firm had revenue of $173.93 million during the quarter, compared to analysts' expectations of $174.48 million. TransMedics Group had a return on equity of 30.17% and a net margin of 31.43%.The business's quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter last year, the business earned $0.70 earnings per share. On average, equities analysts forecast that TransMedics Group will post 2.48 earnings per share for the current year.

Insider Activity at TransMedics Group

In related news, insider Anil P. Ranganath sold 864 shares of TransMedics Group stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total transaction of $120,199.68. Following the transaction, the insider directly owned 13,091 shares in the company, valued at approximately $1,821,219.92. The trade was a 6.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David Weill sold 3,571 shares of TransMedics Group stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $146.82, for a total value of $524,294.22. Following the transaction, the director owned 12,134 shares in the company, valued at $1,781,513.88. This trade represents a 22.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 16,205 shares of company stock valued at $2,353,002 in the last ninety days. Corporate insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently made changes to their positions in TMDX. Royal Bank of Canada lifted its position in shares of TransMedics Group by 47.9% in the first quarter. Royal Bank of Canada now owns 26,582 shares of the company's stock valued at $1,788,000 after acquiring an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of TransMedics Group by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company's stock valued at $1,314,000 after acquiring an additional 868 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock valued at $34,145,000 after acquiring an additional 86,721 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of TransMedics Group by 13.5% in the second quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company's stock valued at $1,059,000 after acquiring an additional 938 shares in the last quarter. Finally, M&T Bank Corp purchased a new position in shares of TransMedics Group in the second quarter valued at about $209,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.